RS
LUCD icon

R Squared’s Lucid Diagnostics LUCD Stock Holding History

R Squared’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7K Buy
21,516
+3,077
+17% +$3.92K 0.01% 454
2025
Q4 		$20.1K Buy
+18,439
New +$20.6K 0.01% 493

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

R Squared's LUCD Position: Q1 2026 in Review

R Squared increased its Lucid Diagnostics (LUCD) stake by 17% in Q1 2026, buying an estimated $3.92K and bringing the position to 21,516 shares worth $24.7K. The position accounts for 0.01% of the portfolio, ranked #454.

R Squared first reported a position in LUCD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • R Squared held 21,516 shares of Lucid Diagnostics worth $24.7K as of Q1 2026.
  • R Squared bought 3,077 Lucid Diagnostics shares in Q1 2026, an estimated $3.92K.
  • Lucid Diagnostics made up 0.01% of R Squared's portfolio in Q1 2026, its #454 holding.
  • R Squared first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.